Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Genetic variants, haplotype determination, and function of novel alleles of CYP2B6 in a Han Chinese population.
Zhang LQ et al.
Heliyon, 2024
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Autoinflammatory Keratinization Disease With Hepatitis and Autism Reveals Roles for JAK1 Kinase Hyperactivity in Autoinflammation.
Takeichi T et al.
Frontiers in Immunology, 2021
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.
Bushyakanist A et al.
Pharmacogenomics and Personalized Medicine, 2015
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.
Damronglerd P et al.
Pharmacogenomics and Personalized Medicine, 2015
Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Sukasem C et al.
Infection, 2014
CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W et al.
International Journal of Antimicrobial Agents, 2014
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Manosuthi W et al.
Antimicrobial Agents and Chemotherapy, 2014
Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.
Martis S et al.
The Pharmacogenomics Journal, 2013
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W et al.
Antimicrobial Agents and Chemotherapy, 2013
High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
Sukasem C et al.
Drug Metabolism and Pharmacokinetics, 2013
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C et al.
British Journal of Clinical Pharmacology, 2012
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
Mukonzo JK et al.
British Journal of Clinical Pharmacology, 2009
Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.
Davaalkham J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2007
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2004